2021 Investor Day

Strategic capital allocation framework Capital deployed over last 3 years (through June 30, 2021) Higher priority 33% 1% $2.0B 36% ■ Reinvest in R&D ■ M&A ■ Dividends ■ Share repurchase 30% Lower priority Reinvest for growth Reinvest in product development for high-return organic growth 7% of FY 2021 revenue invested in R&D Pursue M&A Actively evaluate potential acquisitions Pursue targets aligned with long-term strategic goals and financial objectives Support dividends • Regular return of cash to shareholders through dividend at a level that is meaningful and sustained Opportunistically repurchase shares Opportunistic repurchase of shares Current program suspended following acquisitions of MatrixCare and Propeller © 2021 ResMed | 2021 Investor Day – Sept 8, 2021 - Disciplined focus on ROIC and delivering total return 84

View entire presentation